Literature DB >> 29158263

High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel.

Valeria Tomati1, Emanuela Pesce1, Emanuela Caci1, Elvira Sondo1, Paolo Scudieri2, Monica Marini1, Felice Amato3,4, Giuseppe Castaldo3,4, Roberto Ravazzolo1,5, Luis J V Galietta2, Nicoletta Pedemonte6.   

Abstract

In cystic fibrosis, deletion of phenylalanine 508 (F508del) in the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel causes misfolding and premature degradation. One possible approach to reducing the detrimental health effects of cystic fibrosis could be the identification of proteins whose suppression rescues F508del-CFTR function in bronchial epithelial cells. However, searches for these potential targets have not yet been conducted, particularly in a relevant airway background using a functional readout. To identify proteins associated with F508del-CFTR processing, we used a high-throughput functional assay to screen an siRNA library targeting 6,650 different cellular proteins. We identified 37 proteins whose silencing significantly rescued F508del-CFTR activity, as indicated by enhanced anion transport through the plasma membrane. These proteins included FAU, UBE2I, UBA52, MLLT6, UBA2, CHD4, PLXNA1, and TRIM24, among others. We focused our attention on FAU, a poorly characterized protein with unknown function. FAU knockdown increased the plasma membrane targeting and function of F508del-CFTR, but not of wild-type CFTR. Investigation into the mechanism of action revealed a preferential physical interaction of FAU with mutant CFTR, leading to its degradation. FAU and other proteins identified in our screening may offer a therapeutically relevant panel of drug targets to correct basic defects in F508del-CFTR processing.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  chloride channel; cystic fibrosis; cystic fibrosis transmembrane conductance regulator (CFTR); high-throughput screening (HTS); interactome; small interfering RNA (siRNA)

Mesh:

Substances:

Year:  2017        PMID: 29158263      PMCID: PMC5787799          DOI: 10.1074/jbc.M117.816595

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

3.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

4.  fau cDNA encodes a ubiquitin-like-S30 fusion protein and is expressed as an antisense sequence in the Finkel-Biskis-Reilly murine sarcoma virus.

Authors:  L Michiels; E Van der Rauwelaert; F Van Hasselt; K Kas; J Merregaert
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

5.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function.

Authors:  Tsukasa Okiyoneda; Guido Veit; Johanna F Dekkers; Miklos Bagdany; Naoto Soya; Haijin Xu; Ariel Roldan; Alan S Verkman; Mark Kurth; Agnes Simon; Tamas Hegedus; Jeffrey M Beekman; Gergely L Lukacs
Journal:  Nat Chem Biol       Date:  2013-05-12       Impact factor: 15.040

6.  Chemical and biological approaches synergize to ameliorate protein-folding diseases.

Authors:  Ting-Wei Mu; Derrick Sek Tong Ong; Ya-Juan Wang; William E Balch; John R Yates; Laura Segatori; Jeffery W Kelly
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

7.  Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.

Authors:  Elvira Sondo; Valeria Tomati; Emanuela Caci; Alessia Isabella Esposito; Ulrich Pfeffer; Nicoletta Pedemonte; Luis J V Galietta
Journal:  Am J Physiol Cell Physiol       Date:  2011-07-13       Impact factor: 4.249

8.  Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation.

Authors:  Valeria Tomati; Elvira Sondo; Andrea Armirotti; Emanuela Caci; Emanuela Pesce; Monica Marini; Ambra Gianotti; Young Ju Jeon; Michele Cilli; Angela Pistorio; Luca Mastracci; Roberto Ravazzolo; Bob Scholte; Ze'ev Ronai; Luis J V Galietta; Nicoletta Pedemonte
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

9.  Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.

Authors:  Ambra Gianotti; Raffaella Melani; Emanuela Caci; Elvira Sondo; Roberto Ravazzolo; Luis J V Galietta; Olga Zegarra-Moran
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

Review 10.  CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now.

Authors:  Aoife O'Shaughnessy; Brian Hendrich
Journal:  Biochem Soc Trans       Date:  2013-06       Impact factor: 5.407

View more
  14 in total

1.  Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation.

Authors:  Sara Canato; João D Santos; Ana S Carvalho; Kerman Aloria; Margarida D Amaral; Rune Matthiesen; André O Falcao; Carlos M Farinha
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

2.  Folding Status Is Determinant over Traffic-Competence in Defining CFTR Interactors in the Endoplasmic Reticulum.

Authors:  João D Santos; Sara Canato; Ana S Carvalho; Hugo M Botelho; Kerman Aloria; Margarida D Amaral; Rune Matthiesen; Andre O Falcao; Carlos M Farinha
Journal:  Cells       Date:  2019-04-14       Impact factor: 6.600

3.  Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.

Authors:  Andrea Armirotti; Valeria Tomati; Elizabeth Matthes; Guido Veit; Deborah M Cholon; Puay-Wah Phuan; Clarissa Braccia; Daniela Guidone; Martina Gentzsch; Gergely L Lukacs; Alan S Verkman; Luis J V Galietta; John W Hanrahan; Nicoletta Pedemonte
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

4.  Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue.

Authors:  Rachel A Hodos; Matthew D Strub; Shyam Ramachandran; Li Li; Paul B McCray; Joel T Dudley
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

5.  Analysis of multiple gene co-expression networks to discover interactions favoring CFTR biogenesis and ΔF508-CFTR rescue.

Authors:  Matthew D Strub; Long Gao; Kai Tan; Paul B McCray
Journal:  BMC Med Genomics       Date:  2021-10-30       Impact factor: 3.622

6.  Epigenetic regulation of inflammation by microRNAs in post-infectious bronchiolitis obliterans.

Authors:  Ruth P Duecker; Ines De Mir Messa; Silvija-Pera Jerkic; Annalena Kochems; Gabriele Gottwald; Antonio Moreno-Galdó; Martin Rosewich; Lucia Gronau; Stefan Zielen; Andreas Geburtig-Chiocchetti; Hermann Kreyenberg; Ralf Schubert
Journal:  Clin Transl Immunology       Date:  2022-02-21

7.  Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.

Authors:  Valeria Capurro; Valeria Tomati; Elvira Sondo; Mario Renda; Anna Borrelli; Cristina Pastorino; Daniela Guidone; Arianna Venturini; Alessandro Giraudo; Sine Mandrup Bertozzi; Ilaria Musante; Fabio Bertozzi; Tiziano Bandiera; Federico Zara; Luis J V Galietta; Nicoletta Pedemonte
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 8.  Recent Strategic Advances in CFTR Drug Discovery: An Overview.

Authors:  Marco Rusnati; Pasqualina D'Ursi; Nicoletta Pedemonte; Chiara Urbinati; Robert C Ford; Elena Cichero; Matteo Uggeri; Alessandro Orro; Paola Fossa
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

Review 9.  CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2020-02-21       Impact factor: 5.810

Review 10.  Proteomics and Metabolomics for Cystic Fibrosis Research.

Authors:  Nara Liessi; Nicoletta Pedemonte; Andrea Armirotti; Clarissa Braccia
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.